Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126894951 | 12689495 | 1 | I | 20111205 | 20160826 | 20160826 | EXP | US-ROCHE-1022589 | ROCHE | , HAZRA R, VAN DYKE R, YILDIRIM C, CRAIN M, SEAGE G, CIVITELLO L, ELLIS A, BUTLER L AND RICH K ANTIRETROVIRAL EXPOSURE DURING PREGNANCY AND ADVERSE OUTCOMES IN HIV-EXPOSED UNINFECTED INFANTS AND CHILDREN USING A TRIGGER-BASED DESIGN. AIDS 2016;30 (1):133-144. | 0.00 | N | Y | 0.00000 | 20160826 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126894951 | 12689495 | 1 | SS | Nelfinavir | NELFINAVIR | 1 | Transplacental | U | 0 | ||||||||||
| 126894951 | 12689495 | 2 | PS | Saquinavir | SAQUINAVIR | 1 | Transplacental | U | 21785 | ||||||||||
| 126894951 | 12689495 | 3 | SS | Enfuvirtide | ENFUVIRTIDE | 1 | Transplacental | 21481 | SOLUTION FOR INJECTION | ||||||||||
| 126894951 | 12689495 | 4 | SS | DIDANOSINE. | DIDANOSINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 5 | SS | EMTRICITABINE | EMTRICITABINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 6 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 7 | SS | STAVUDINE. | STAVUDINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 8 | SS | TENOFOVIR DISOPROXIL FUMARATE. | TENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 9 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 10 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 11 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 12 | SS | ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 13 | SS | DARUNAVIR | DARUNAVIR | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 14 | SS | FOSAMPRENAVIR CALCIUM | FOSAMPRENAVIR CALCIUM | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 15 | SS | LOPINAVIR | LOPINAVIR | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 16 | SS | RITONAVIR. | RITONAVIR | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 17 | SS | COCAINE | COCAINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 18 | SS | RALTEGRAVIR. | RALTEGRAVIR | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 19 | SS | MARAVIROC | MARAVIROC | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 20 | SS | ETRAVIRINE | ETRAVIRINE | 1 | Transplacental | 0 | |||||||||||
| 126894951 | 12689495 | 21 | C | METHADONE HYDROCHLORIDE. | METHADONE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126894951 | 12689495 | 1 | Product used for unknown indication |
| 126894951 | 12689495 | 2 | Product used for unknown indication |
| 126894951 | 12689495 | 3 | Product used for unknown indication |
| 126894951 | 12689495 | 4 | Product used for unknown indication |
| 126894951 | 12689495 | 5 | Product used for unknown indication |
| 126894951 | 12689495 | 6 | Product used for unknown indication |
| 126894951 | 12689495 | 7 | Product used for unknown indication |
| 126894951 | 12689495 | 8 | Product used for unknown indication |
| 126894951 | 12689495 | 9 | Product used for unknown indication |
| 126894951 | 12689495 | 10 | Product used for unknown indication |
| 126894951 | 12689495 | 11 | Product used for unknown indication |
| 126894951 | 12689495 | 12 | Product used for unknown indication |
| 126894951 | 12689495 | 13 | Product used for unknown indication |
| 126894951 | 12689495 | 14 | Product used for unknown indication |
| 126894951 | 12689495 | 15 | Product used for unknown indication |
| 126894951 | 12689495 | 16 | Product used for unknown indication |
| 126894951 | 12689495 | 17 | Product used for unknown indication |
| 126894951 | 12689495 | 18 | Product used for unknown indication |
| 126894951 | 12689495 | 19 | Product used for unknown indication |
| 126894951 | 12689495 | 20 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126894951 | 12689495 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126894951 | 12689495 | Blood lactic acid increased | |
| 126894951 | 12689495 | Dyslipidaemia | |
| 126894951 | 12689495 | Foetal exposure during pregnancy | |
| 126894951 | 12689495 | Growth retardation | |
| 126894951 | 12689495 | Insulin resistance | |
| 126894951 | 12689495 | Left ventricular dysfunction | |
| 126894951 | 12689495 | Low birth weight baby | |
| 126894951 | 12689495 | Nervous system disorder | |
| 126894951 | 12689495 | Obesity | |
| 126894951 | 12689495 | Ventricular hypertrophy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |